EUCTR2018-000970-31-GB进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8 Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed Written Informed Consent
- •a) Subjects will be required to provide a written informed consent.
- •2)Type of Participant and Target Disease Characteristics
- •a) Males and Females, ages 18 or age of majority or older.
- •b) Left ventricular EF <45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months.
- •c) On stable chronic guideline-directed therapy for HF including chronic loop diuretics, ACEi, ARBs, MRAs, ARNI or / and ß-blockers as tolerated, with no changes of these medications in the past 2 weeks.
- •d) Not applicable per Protocol Amendment 3.0
- •e) Not applicable per Protocol Amendment 3.0
- •f) Not applicable per Protocol Amendment 3.0
- •g) Elevated natriuretic peptides (N terminal-pro BNP [NT-proBNP] = 200 pg/mL or brain natriuretic peptide [BNP] = 60 pg/mL). For subjects with atrial fibrillation, NT-proBNP = 400 pg/mL or BNP = 120 pg/mL.
- •h) Estimated glomerular filtration rate (eGFR) between 30 and 80 mL/min/1.73m2.
- •3) Age and Reproductive Status
- •a) Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of each study treatment.
- •b) Women must not be breastfeeding.
- •c) WOCBP must agree to follow instructions for methods of highly effective contraception for 31 days after discontinuation (duration of study drug exposure plus 30 days duration of one ovulatory cycle).
- •d) Males who are sexually active with WOCBP must require these partners to follow instructions for highly effective methods of contraception for 91 days after discontinuation (duration of study drug plus 90 days (duration of sperm turnover).
- •e) Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements, but still must undergo pregnancy testing as described in this section.
- •Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of < 1% when used consistently and correctly.
- •Local laws and regulations may require use of alternative and/or additional contraception methods.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1)Target Disease Exceptions
- •a) SBP < 115 mm Hg or > 180 mm Hg at screening or pre-randomization.
- •b) Heart rate < 50 beats per minute (bpm) or > 120 bpm at screening or pre-randomization.
- •c) Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic or uncorrected severe valvular disease as defined by American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC) criteria.
- •d) Patients with urinary/prostate disorders with urinary retention/significant bladder dysfunction or urinary incontinence.
- •e) Inability to comply with the serial urine collection procedures.
- •f) Pericardial tamponade or constrictive pericarditis.
- •g) Left ventricular (LV) assist device or prior heart transplant.
- •h) Hospitalized for acute decompensated HF in the previous month.
- •i) New York Heart Association (NYHA) Class IV symptoms of HF.
- •j) Hospitalized with acute coronary syndrome, coronary revascularization or acute myocardial infarction during the previous 90 days prior to screening.
- •k) Have a history of a cerebral vascular accident (cerebrovascular accident [CVA] or stroke) or of a transient ischemic attack (TIA) during the previous 90 days prior to screening.
- •l) Considered clinically unstable for any condition.
- •m) Serious comorbid non-cardiovascular disease in which the life expectancy of the subject is < 3 months.
- •n) Liver disease defined as history of cirrhosis with evidence of portal hypertension such as varices, or encephalopathy, or total bilirubin > 3 mg/dL (> 34.2 µmol/L) or significant elevation of liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT] > 3 times the upper limit of normal).
- •o) Prior solid organ transplant.
- •2)Prior/Concomitant Therapy
- •a) Patients taking thiazides / metolazone or potassium-sparing diuretics (with the exception of spironolactone or eplerenone at doses = 50 mg/day which are allowed).
- •3)Physical and Laboratory Test Findings
- •a) Have persistent abnormal serum electrolytes not resolved between screening and start of the study drug infusion, as defined by any of the following:
- •i)A sodium (Na+) concentration < 130 or > 145 mEq/L (mmol/L).
- •ii)A potassium (K+) concentration < 3.2 or > 5.5 mEq/L (mmol/L).
- •b) Have severe anemia, as documented by a hemoglobin < 9 g/dL (< 5.59 mmol/L).
- •4)Allergies and Adverse Drug Reaction
- •a) Any history of allergic reaction to components of BMS-986231, Captisol® or potassium acetate.
- •b) Any history of allergic reactions to furosemide.
- •5)Other Exclusion Criteria
- •a) Prisoners or participants who are involuntarily incarcerated. (Note: under certain specific circumstances a person who has been imprisoned may be included or permitted to continue as a participant. Strict conditions apply and Bristol-Myers Squibb’s approval is required).
- •b) Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
- •c) Participation in an investigational clinical drug study within 30 days or 5 elimination half-lives, (whichever is longer) prior to randomization.
- •d) Prior participation and treatment in a study using BMS-986231.
- •e) Alcohol beverage consumption within 6 hours prior to randomization.
- •f) Body weight < 45 kg or = 140 kg.
- •g) Site personel and their families.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the effects of JZP-110 (study drug) on driving performance in subjects with excessive sleepiness due to NarcolpesyTreatment of excessive sleepiness in adult patients with narcolepsyMedDRA version: 20.0Level: HLTClassification code 10028716Term: Narcolepsy and associated conditionsSystem Organ Class: 100000004873EUCTR2015-003931-36-DEJazz Pharmaceuticals Inc.24
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment with Immunosuppressants. - C08-001EUCTR2009-014669-13-GBAlexion Pharmaceuticals Inc.24
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive Sleepiness Due to NarcolepsyNarcolepsysleep disease10040998NL-OMON47913JAZZ Pharmaceuticals Inc.33
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin Treatment twice daily in Patients with Type 2 DiabetesType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-004032-48-SEAstraZeneca AB36
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive Sleepiness Due to Obstructive Sleep ApneaObstructive sleep apneatemporary respiratory arrest10040998NL-OMON47629JAZZ Pharmaceuticals Inc.40